Market Performance and Valuation
Shares of Palantir Technologies (NASDAQ: PLTR) have faced significant headwinds, declining more than 35% from their 52-week high of $207.52. As of mid-June 2026, the stock is down approximately 26% year-to-date, presenting a stark contrast to the company’s underlying business momentum.
Despite the stock price correction, Palantir reported an 85% year-over-year revenue increase in the first quarter of 2026, reaching $1.63 billion. U.S. commercial revenue, a key driver for the firm, surged 133% to $595 million, bolstered by major contracts with companies like Airbus, Bain, and GE Aerospace. CFO David Glazer noted that this marks the eleventh consecutive quarter of accelerating revenue growth.
Growth vs. Valuation Concerns
The discrepancy between strong business performance and stock price decline highlights investor anxiety regarding Palantir’s valuation. With a market capitalization of roughly $306 billion against trailing-12-month revenue of $5.2 billion, the company trades at a price-to-earnings ratio exceeding 140. Analysts argue that such a valuation leaves little room for error, especially as the company faces a challenging macro environment and international contract uncertainties, including a pending review of a $441 million deal with the U.K. National Health Service.
Institutional Outlook
Despite these risks, institutional support remains firm. On June 5, Rosenblatt reiterated a ‘Buy’ rating on Palantir with a price target of $225, citing broad-based adoption of the company’s AI Platform (AIP) across both public and private sectors. Furthermore, Palantir recently announced a multi-year expansion with GNP Seguros, Mexico’s largest insurance firm, signaling continued international commercial momentum.